Stockscreener 앱 받기
6.28
5.85%
-0.39
시간 외 거래:
6.28
전일 마감가:
$6.67
열려 있는:
$6.67
하루 거래량:
177.44K
Relative Volume:
0.45
시가총액:
$354.41M
수익:
-
순이익/손실:
$-72.89M
주가수익비율:
-2.595
EPS:
-2.42
순현금흐름:
$-68.47M
1주 성능:
-4.27%
1개월 성능:
-2.03%
6개월 성능:
-11.67%
1년 성능:
-36.88%
1일 변동 폭
$6.20
$6.67
1주일 범위
$6.20
$7.205
52주 변동 폭
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
명칭
Astria Therapeutics Inc
전화
617-349-1971
주소
22 BOSTON WHARF ROAD, BOSTON
ATXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
6.28 | 393.91M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | TD Cowen | Buy |
| 2023-03-28 | 개시 | Evercore ISI | Outperform |
Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스
How high can Astria Therapeutics Inc. stock goFree Accurate Technical Trend Reversal Picks - Newser
How Astria Therapeutics Inc. stock performs during market volatilityFree Momentum Based Equity Trading Plan - Newser
Is Astria Therapeutics Inc. showing signs of accumulationInvestment Roadmap for High Potential Stocks - Newser
Price action breakdown for Astria Therapeutics Inc.AI-Based Reversal Point Prediction Signal - Newser
Is it time to cut losses on Astria Therapeutics Inc.Daily Profit Watch With Forecast Confidence - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionPredictable Income Summary for Long-Term Trades - Newser
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
Can trapped investors hope for a rebound in Astria Therapeutics Inc.Free Alpha Driven Watchlist With Alerts - Newser
Astria Therapeutics Inc. stock prediction for this weekFree Smart Allocation Stock Pick Insights - Newser
Astria licenses rare disease drug Navenibart to Japan’s Kaken Pharma in $32 M deal - BioSpectrum Asia
Astria Therapeutics Inc. stock momentum explainedAsset Safety Selection Using Quantitative Analysis - Newser
How to build a dashboard for Astria Therapeutics Inc. stockFree Short Term Setup With Predictive Chart - Newser
Can Astria Therapeutics Inc. hit a new high this monthWeekly High Conviction Trade Setup Analysis - Newser
Astria Therapeutics shares fall 1.15% intraday after being dropped from multiple Russell indices. - AInvest
Astria Therapeutics licenses navenibart rights to Kaken for HAE - Yahoo Finance
What earnings revisions data tells us about Astria Therapeutics Inc.Free Wealth Building Stock Market Ideas - Newser
How to escape a deep drawdown in Astria Therapeutics Inc.Chart Confirmation Setup with ROI Signals - Newser
Astria Therapeutics’ Strategic Advancements and Market Potential: A Buy Recommendation by Joseph Pantginis - TipRanks
Astria Therapeutics: Strategic Partnership and Promising Phase 3 Trial Justify Buy Rating - TipRanks
Astria Therapeutics Strikes Licensing Deal in Japan - MarketScreener
Astria Therapeutics Licenses Japan Rights to Navenibart in $16mln Deal, Kaken Pharmaceutical to Support Phase 3 Trials and Commercialization - AInvest
Astria Therapeutics Licenses Japan Rights To Navenibart In $16 Mln Deal - Nasdaq
Astria Therapeutics Enters Licensing Deal with Kaken - TipRanks
Astria, Kaken ink deal to develop navenibart for HAE in Japan - MarketScreener
ATXS inks $16M navenibart deal with Kaken; runway now into 2028 | ATXS SEC FilingForm 8-K - Stock Titan
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan - Business Wire
Astria Therapeutics Grants Stock Options to Two New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Will Astria Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsDaily Pick Forecast with Entry Zones - Newser
What catalysts could drive Astria Therapeutics Inc. stock higher in 2025Achieve impressive returns with smart timing - Jammu Links News
Applying sector rotation models to Astria Therapeutics Inc.Low Risk Stock Selection Strategy Guide - Newser
What is Astria Therapeutics Inc. company’s growth strategyMarket-beating performance - Jammu Links News
What institutional investors are buying Astria Therapeutics Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
What are the technical indicators suggesting about Astria Therapeutics Inc.Real-time trading signals for maximum returns - Jammu Links News
Is Astria Therapeutics Inc. a growth stock or a value stockBuild wealth faster with expert stock selection - Jammu Links News
What is the dividend policy of Astria Therapeutics Inc. stockBuild your wealth with consistent stock growth - Jammu Links News
How many analysts rate Astria Therapeutics Inc. as a “Buy”Consistent triple-digit returns - Jammu Links News
Will Astria Therapeutics Inc. continue its uptrendMulti-Year Investment Performance Summary Report - Newser
What makes Astria Therapeutics Inc. stock price move sharplyAchieve rapid portfolio growth with expert guidance - Jammu Links News
Astria Therapeutics Inc (ATXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):